Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has disclosed a change in the securities interests of director Gordon Naylor following his appointment as interim chief executive officer. The filing details that Naylor has been granted 39,579 Restricted Share Units under the CSL Limited Performance Rights Plan, held via custodian Solium Nominees (Australia) Pty Ltd, with no cash consideration involved.
The award is described as a one-off equity grant linked to Naylor’s new leadership role, aligning his remuneration more closely with shareholder outcomes and the company’s future performance. Following the change, Naylor’s existing direct and indirect holdings of ordinary shares remain unchanged, while the newly granted Restricted Share Units add a performance-based equity component to his overall stake in CSL.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$155.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company specializing in the research, development and manufacture of biotherapies and vaccines. The company focuses on treating serious and rare conditions, supplying plasma-derived and recombinant therapies as well as influenza vaccines to healthcare systems and patients worldwide.
Average Trading Volume: 1,180,261
Technical Sentiment Signal: Sell
Current Market Cap: A$68.43B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.